What is it about?
Schizophrenia is a complex, chronic and widespread psychiatric problem that affects about 1% of the world’s total population. The risk of developing Schizophrenia is about the same for men and women, but there are gender differences in the development of the disease. Doxycycline and Minocycline are tetracyclines with potent antioxidant, anti-inflammatory, immunomodulatory, neuroprotective, antidepressant, anti-anxiety, antipsychotic, memory enhancing, neuroprotective properties, and better pharmacokinetic profiles. This tetracycline is used to treat psychosis and to evaluate its protective effects against Ketamine-induced behavioral, biochemical, neurochemical, and histological changes in mice.
Featured Image
Photo by micheile dot com on Unsplash
Why is it important?
Pretreatment with the combination of Doxycycline and Minocycline showed valuable antipsychotic activity that would be exploited due to its antibiotic activity. The combination of the two antibiotics ameliorated behavioral changes as represented by hyperlocomotion and stereotype behavior, increased immobility, and increased step-down latency on the 7th, 14th, and 21st days respectively. Further, the combination showed biochemical, neurochemical, and histological changes as assessed on the 22nd day.
Perspectives
Read the Original
This page is a summary of: Effect of combination of Doxycycline and Minocycline antibiotic on Ketamine induced experimental Schizophrenia in mice, Journal of Science and Technological Researches, June 2022, Journal of Science and Technological Researches,
DOI: 10.51514/jstr.4.2.2022.14-43.
You can read the full text:
Resources
Contributors
The following have contributed to this page